Bempedoic acid is a novel lipid-lowering drug recently approved for the treatment of dyslipidemia. This review describes the pharmacology of bempedoic acid and its clinical role in patients with dyslipidemia. Bempedoic acid, via its active coenzyme A (CoA) form, inhibits adenosine triphosphate (ATP)...
View article Review of recent clinical trials and their impact on the treatment of hypercholesterolemia Johnathon SethParham,Anne CarolGoldberg, inProgress in Cardiovascular Diseases, 2022 Bempedoic acid Bempedoic acid(BPA) is a first in class, oral, inhibitor of cholesterol biosynthesis. It acts by ...
But, if patients are intolerant to statins then adding bempedoic acid to reduce LDL levels should be considered. Funding No funding was received for this manuscript. Author contributions Dr. Yarrarapu and Dr. Goyal conceived the notion of composing this review article, while Dr. Panchal and Dr....
现代药物与临床 Drugs & Clinic 第 30 卷第 11 期 2015 年 11 月·1417· • 未来药物 • 新型降脂药物 bempedoic acid 褚小琴 1,闫少杰 2,张远 2,李树军 2,王平保 2* 1. 天津医科大学 研究生院,天津 300070 2. 天津药物研究院 化学制药部,天津 300193 摘要:血脂异常是心血管疾病的一个高危因素,...
Bempedoic Acid (BA) is a novel Lipid-Lowering Therapy (LLT). We performed a systematic review and meta-analysis to assess the efficacy and safety of BA in patients with hypercholesterolemia. PubMed, Scopus, and Cochrane library databases were searched fo
This 32-country randomized clinical trial assesses the effects of bempedoic acid on cardiovascular outcomes in statin-intolerant patients receiving
Application (MAA) for bempedoic acid and the bempedoic acid/ezetimibe fixed dose combination tablet by the European Medicines Agency (EMA). Validation confirms that the application is complete and commences the scientific review process by the EMA's Committee for Medicinal Products for Human Use (...
Therefore, the aim of this article is to conduct a comprehensive evaluation of the impact of bempedoic acid on the incidence of cardiovascular events. Methods: A systematic review and meta-analysis of randomized controlled trials pertaining to bempedoic acid was carried out. We conducted a ...
Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.doi:10.1097/crd.0000000000000218Nicole K ZagelbaumSrikanth YandrapalliChristopher NaborsWilliam H Frishman...
Furthermore, bempedoic acid is a prodrug that becomes activated by an enzyme expressed primarily in the liver, allowing it to avoid the potential myotoxicity associated with statin therapy. The purpose of this review is to summarize the major clinical studies evaluating bempedoic acid and describe ...